Unraveling challenges in accessing quality and affordable medicines in Indonesia is a complex issue affecting millions. Equitable availability of essential drugs, especially in remote areas, remains a significant undertaking. High drug prices, limited distribution, and quality concerns often hinder people from receiving optimal healthcare, a multifaceted problem demanding comprehensive solutions.
One of the main unraveling challenges is the relatively high price of medicines for a large segment of the population. While the government strives to control prices, production costs, raw material imports, and distributor profit margins often render medications unaffordable, particularly for the middle to lower-income brackets.
Uneven medicine distribution also presents a serious problem. Healthcare facilities in remote areas frequently suffer from a shortage of essential drug supplies. Limited transportation and logistical infrastructure make drug delivery expensive and time-consuming, further complicating efforts to address this unraveling challenges holistically.
The issue of medicine quality also warrants attention. The circulation of counterfeit or substandard drugs remains a threat. This not only causes financial harm to patients but also endangers their health, as such medications may be ineffective or even lead to dangerous side effects, adding another layer to the problem.
A lack of public awareness regarding rational drug use further exacerbates the unraveling challenges. Consuming medication without a doctor’s prescription, failing to complete a prescribed dosage, or the improper use of antibiotics can lead to drug resistance, worsening existing health issues and creating new ones for the community.
The Indonesian government has undertaken various efforts to tackle this unraveling challenges, including strengthening drug price regulations, increasing generic drug production, and expanding distribution networks. The National Health Insurance (JKN) program, through BPJS Kesehatan, also aims to ensure widespread access to medicines for all citizens.
However, these efforts must be continuously enhanced. Greater investment is needed in pharmaceutical infrastructure, including local production facilities capable of manufacturing active pharmaceutical ingredients. Diversifying sources for raw material imports is also crucial to reduce dependency and curb prices, making medicines more accessible.
Transparency throughout the drug supply chain, from manufacturers to pharmacies, is paramount to prevent cartel practices or hoarding. Strict oversight from the National Agency of Drug and Food Control (BPOM) and related institutions can help guarantee the quality and availability of safe medicines for public consumption.